Improved treatment response and bone density in patients with chronic hepatitis B (CHB) switched to tenofovir alafenamide (TAF) from other nucleos (t)ide analogue: 96-week results from a prospective multinational study Ogawa, E., Jun, D., Toyoda, H., Hsu, Y., Yoon, E., Ahn, S., Do, S., Huy Trinh, Takahashi, H., Enomoto, M., Yasuda, S., Tseng, C., Yeh, M., Kawashima, K., Lee, H., Inoue, K., Haga, H., Ai-Thien Do, Maeda, M., Hoang, J., Cheung, R. C., Ueno, Y., Eguchi, Y., Furusyo, N., Yu, M., Tanaka, Y., Nguyen, M. ELSEVIER. 2022: S875-S876

View details for Web of Science ID 000826275104286